Inozyme Funding: $116M Raised, Series A (2019)

Inozyme funding overview

Inozyme is based in Cambridge. Inozyme has raised $116M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in January 2019. The round record for Inozyme runs through 2019; nothing later has been disclosed. Investors on record include Longitude Capital, New Enterprise Associates (NEA), Novo Ventures, Sanofi Ventures, BioMarin Pharmaceutical, TD Securities and 1 others. 7 distinct backers are named across the disclosed rounds.

Inozyme at a glance

Total raised: $116M
Latest round: Series A
Latest round date: January 2019
Headquarters: Cambridge
Notable investors: Longitude Capital, New Enterprise Associates (NEA), Novo Ventures, Sanofi Ventures, BioMarin Pharmaceutical, TD Securities, RA Capital

Frequently asked about Inozyme funding

How much has Inozyme raised?: Inozyme has raised $116M in total disclosed funding across the rounds on record.
Who has invested in Inozyme?: Longitude Capital, New Enterprise Associates (NEA), Novo Ventures, Sanofi Ventures, BioMarin Pharmaceutical, TD Securities are named among the investors backing Inozyme.
What was the latest Inozyme funding round?: The most recent disclosed round is a Series A, announced in January 2019.
Where is Inozyme based?: Inozyme is based in Cambridge.
When did Inozyme last raise?: The last disclosed Inozyme round closed in January 2019 at Series A.

We update the Inozyme record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related companies in Cambridge and their backers are listed below.

Inozyme Funding: $116M Raised, Series A (2019)

Inozyme funding overview

Inozyme at a glance

Frequently asked about Inozyme funding

Companies related to Inozyme (36)

Browse related funding lists (9)